Cargando…

VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody

BACKGROUND: In gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker. METHODS: Biopsy specimens from both primary lesions a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fushida, Sachio, Oyama, Katsunobu, Kinoshita, Jun, Yagi, Yasumichi, Okamoto, Kouichi, Tajima, Hidehiro, Ninomiya, Itasu, Fujimura, Takashi, Ohta, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804591/
https://www.ncbi.nlm.nih.gov/pubmed/24204159
http://dx.doi.org/10.2147/OTT.S51916
_version_ 1782288177361321984
author Fushida, Sachio
Oyama, Katsunobu
Kinoshita, Jun
Yagi, Yasumichi
Okamoto, Kouichi
Tajima, Hidehiro
Ninomiya, Itasu
Fujimura, Takashi
Ohta, Tetsuo
author_facet Fushida, Sachio
Oyama, Katsunobu
Kinoshita, Jun
Yagi, Yasumichi
Okamoto, Kouichi
Tajima, Hidehiro
Ninomiya, Itasu
Fujimura, Takashi
Ohta, Tetsuo
author_sort Fushida, Sachio
collection PubMed
description BACKGROUND: In gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker. METHODS: Biopsy specimens from both primary lesions and peritoneal metastasis, and if possible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-linked immunosorbent assay. RESULTS: VEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels in the large group were significantly higher than in the small group (P < 0.0001). Serum VEGF and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 8 months of palliation from systemic bevacizumab. CONCLUSION: Anti-VEGF therapies are promising, and the ascites VEGF level is an important marker in managing patients with gastric cancer and peritoneal metastasis.
format Online
Article
Text
id pubmed-3804591
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38045912013-11-07 VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody Fushida, Sachio Oyama, Katsunobu Kinoshita, Jun Yagi, Yasumichi Okamoto, Kouichi Tajima, Hidehiro Ninomiya, Itasu Fujimura, Takashi Ohta, Tetsuo Onco Targets Ther Original Research BACKGROUND: In gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker. METHODS: Biopsy specimens from both primary lesions and peritoneal metastasis, and if possible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-linked immunosorbent assay. RESULTS: VEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels in the large group were significantly higher than in the small group (P < 0.0001). Serum VEGF and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 8 months of palliation from systemic bevacizumab. CONCLUSION: Anti-VEGF therapies are promising, and the ascites VEGF level is an important marker in managing patients with gastric cancer and peritoneal metastasis. Dove Medical Press 2013-10-16 /pmc/articles/PMC3804591/ /pubmed/24204159 http://dx.doi.org/10.2147/OTT.S51916 Text en © 2013 Fushida et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fushida, Sachio
Oyama, Katsunobu
Kinoshita, Jun
Yagi, Yasumichi
Okamoto, Kouichi
Tajima, Hidehiro
Ninomiya, Itasu
Fujimura, Takashi
Ohta, Tetsuo
VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody
title VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody
title_full VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody
title_fullStr VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody
title_full_unstemmed VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody
title_short VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody
title_sort vegf is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of vegf in ascites and efficacy of anti-vegf monoclonal antibody
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804591/
https://www.ncbi.nlm.nih.gov/pubmed/24204159
http://dx.doi.org/10.2147/OTT.S51916
work_keys_str_mv AT fushidasachio vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT oyamakatsunobu vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT kinoshitajun vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT yagiyasumichi vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT okamotokouichi vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT tajimahidehiro vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT ninomiyaitasu vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT fujimuratakashi vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody
AT ohtatetsuo vegfisatargetmoleculeforperitonealmetastasisandmalignantascitesingastriccancerprognosticsignificanceofvegfinascitesandefficacyofantivegfmonoclonalantibody